Citations

Mayo Clinic

Clear

720 citation(s) found for "Núñez, Gabriel".

Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients
Wojenski, Daniel, Bartoo, Gabriel , Merten, Julianna A., Dierkhising, Ross , Barajas, M, Wilson, John , Plevak, Matt, Litzow, Mark R. , Patnaik, Mrinal M. , Hashmi, Shahrukh K. , el‐Azhary, Rokea A. , Hogan, William J. , Wolf, Robert Christian

Transplant Infectious Disease | February 6, 2015 | Volume: 17 | Issue: 2 | Pages: 250-258

10.1111/tid.12367 | PMID 25661996 Get It

AbstractBackgroundVoriconazole is a commonly used antifungal medication in allogeneic hematopoietic stem cell transplantation (allo‐HSCT) patients. In solid organ transplantation, voriconazole use has been associated with the development of cutaneous squamous cell carcinoma (SCC). We sought to determine if voriconazole use was associated with SCC in patients undergoing allo‐HSCT.MethodsWe retrospectively reviewed consecutive adult patients who underwent allo‐HSCT at Mayo Clinic from January 2007 through July 2012. Multivariable Cox models were created to assess the relationship of SCC with two time‐dependent voriconazole exposure variables: (i) history of voriconazole exposure (yes/no), and (ii) cumulative days of voriconazole use.ResultsIn our cohort of 381 allo‐HSCT patients, SCC developed in 26 of 312 patients exposed to voriconazole (25 post‐voriconazole) and in 1 of 69 patients who received alternative antifungal agent(s). Cumulative incidence of SCC was estimated to be 19% at 5 years post allo‐transplant. Cumulative days of voriconazole use was found to be a risk factor for SCC, and this relationship persisted in a multivariable model using previously identified risk factors as covariates (hazard ratio 1.859 for each 180 days of use, P < 0.001).ConclusionThis is the first study, to our knowledge, to identify cumulative days of voriconazole use as a risk factor for SCC development following allo‐HSCT, and may help guide appropriate antifungal use in this patient population.
SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer
Budd, G. Thomas , Hobday, Timothy J. , Stewart, James A. , Salim, Muhammad , Cho, Jonathan K., Rinn, Kristine , Albain, Kathy S. , Chew, Helen K. , Burton, Gary V., Moore, Timothy D., Srkalović, Gordan , Flaherty, Lawrence E. , Livingston, Robert B., Lew, Danika L., Budd, George T, Rinn, Kristine J, McGregor, Bradley A. , Barlow, William E. , Moore, Halle C. F. , Isaacs, Claudine , Gralow, Julie R. , Hortobágyi, Gabriel N.

Journal of Clinical Oncology | November 25, 2014 | Volume: 33 | Issue: 1 | Pages: 58-64

10.1200/jco.2014.56.3296 | PMID 25422488 Get It

Purpose To determine the optimal dose and schedule of anthracycline and taxane administration as adjuvant therapy for early-stage breast cancer. Patients and Methods A 2 × 2 factorial design was used to test two hypotheses: (1) that a novel continuous schedule of doxorubicin-cyclophosphamide was superior to six cycles of doxorubicin-cyclophosphamide once every 2 weeks and (2) that paclitaxel once per week was superior to six cycles of paclitaxel once every 2 weeks in patients with node-positive or high-risk node-negative early-stage breast cancer. With 3,250 patients, a disease-free survival (DFS) hazard ratio of 0.82 for each randomization could be detected with 90% power with two-sided α = .05. Overall survival (OS) was a secondary outcome. Results Interim analyses crossed the futility boundaries for demonstrating superiority of both once-per-week regimens and once-every-2-weeks regimens. After a median follow-up of 6 years, a significant interaction developed between the two randomization factors (DFS P = .024; OS P = .010) in the 2,716 patients randomly assigned in the original design, which precluded interpretation of the two factors separately. Comparing all four arms showed a significant difference in OS (P = .040) but not in DFS (P = .11), with all treatments given once every 2 weeks associated with the highest OS. This difference in OS seemed confined to patients with hormone receptor–negative/human epidermal growth factor receptor 2 (HER2) –negative tumors (P = .067), with no differences seen with hormone receptor–positive/HER2-negative (P = .90) or HER2-positive tumors (P = .40). Conclusion Patients achieved a similar DFS with any of these regimens. Subset analysis suggests the hypothesis that once-every-2-weeks dosing may be best for patients with hormone receptor–negative/HER2-negative tumors.
Gene expression profiling and association of circulating lactoferrin level with obesity‐related phenotypes in Latino youth
Kim, Joon Young , Campbell, Latoya E., Shaibi, Gabriel Q. , Coletta, Dawn K. , Coletta, Dawn K

Pediatric Obesity | November 14, 2014 | Volume: 10 | Issue: 5 | Pages: 338-344

10.1111/ijpo.269 | PMID 25394788 Get It

SummaryBackground/ObjectivesLow‐grade inflammation is an underlying feature of obesity and identifying inflammatory markers is crucial to understanding this disease. Therefore, the purpose of this study was twofold: (i) to perform a global microarray analysis and (ii) to investigate the role of lactoferrin (LTF), one of the most altered genes, in relation to obesity in Latino youth.MethodsNon‐diabetic Latino youth (71 males/92 females; 15.6 ± 3.2 years) were studied. A subset of 39 participants was randomly selected for global microarray analysis profiling from the whole blood sample. Serum LTF was compared between lean (n = 78) and overweight/obese (n = 85) participants.ResultsMicroarray analysis revealed that a total of 1870 probes were altered in expression ≥1.2‐fold and P < 0.05 in overweight/obese participants compared with lean. KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis revealed significant enrichment for pathways including toll‐like receptor (TLR) and B cell receptor signalling pathways. LTF and TLR5 were increased in expression by 2.2 and 1.5 fold, respectively, in the overweight/obese participants. Increased LTF concentrations were significantly associated with high risk of obesity‐related phenotypes (all P < 0.05).ConclusionsOur data suggest that increased LTF is associated with obesity risk among Latino youth. This finding is discordant to what has been shown in adults and suggests that age may modulate the association between LTF and obesity‐related health.
Planar Cell Polarity Aligns Osteoblast Division in Response to Substrate Strain
Galea, Gabriel L. , Meakin, Lee B. , Savery, Dawn, Taipaleenmäki, Hanna , Delisser, Peter , Copp, Andrew J. , Wijnen, André J. van , Lanyon, Lance E., Price, Joanna S., Stein, Gary S. , van Wijnen, Andre J

Journal of Bone and Mineral Research | September 29, 2014 | Volume: 30 | Issue: 3 | Pages: 423-435

10.1002/jbmr.2377 | PMID 25264362 Get It

ABSTRACT Exposure of bone to dynamic strain increases the rate of division of osteoblasts and also influences the directional organization of the cellular and molecular structure of the bone tissue that they produce. Here, we report that brief exposure to dynamic substrate strain (sufficient to rapidly stimulate cell division) influences the orientation of osteoblastic cell division. The initial proliferative response to strain involves canonical Wnt signaling and can be blocked by sclerostin. However, the strain-related orientation of cell division is independently influenced through the noncanonical Wnt/planar cell polarity (PCP) pathway. Blockade of Rho-associated coiled kinase (ROCK), a component of the PCP pathway, prevents strain-related orientation of division in osteoblast-like Saos-2 cells. Heterozygous loop-tail mutation of the core PCP component van Gogh-like 2 (Vangl2) in mouse osteoblasts impairs the orientation of division in response to strain. Examination of bones from Vangl2 loop-tail heterozygous mice by µCT and scanning electron microscopy reveals altered bone architecture and disorganized bone-forming surfaces. Hence, in addition to the well-accepted role of PCP involvement in response to developmental cues during skeletal morphogenesis, our data reveal that this pathway also acts postnatally, in parallel with canonical Wnt signaling, to transduce biomechanical cues into skeletal adaptive responses. The simultaneous and independent actions of these two pathways appear to influence both the rate and orientation of osteoblast division, thus fine-tuning bone architecture to meet the structural demands of functional loading. © 2014 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.
Hyperuricemia and Incident Cardiovascular Disease and Noncardiac Vascular Events in Patients with Rheumatoid Arthritis
Kuo, Daniel , Crowson, Cynthia S. , Gabriel, Sherine E., Matteson, Eric L.

International Journal of Rheumatology | August 17, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-7

10.1155/2014/523897 | PMID 25197282 Get It

Objective. To evaluate whether hyperuricemia is a risk factor for cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA).Methods. A population-based inception cohort of patients diagnosed between 1980 and 2007 with adult-onset RA was assembled. A comparison cohort of age- and sex-matched subjects without RA (non-RA) was also assembled. All clinically obtained uric acid values were collected. CVD and noncardiac vascular events were recorded for each patient. Cox proportional hazards models were used to assess the impact of hyperuricemia on development of CVD, mortality, and noncardiac vascular disease.Results. In patients without RA, hyperuricemia was associated with heart failure (HR: 1.95; 95% CI: 1.13–3.39) and CVD (HR: 1.59; 95% CI: 0.99–2.55). In patients with RA, hyperuricemia was not significantly associated with CVD but was significantly associated with peripheral arterial events (HR: 2.52; 95% CI: 1.17–5.42). Hyperuricemia appeared to be more strongly associated with mortality among RA patients (HR: 1.96; 95% CI: 1.45–2.65) than among the non-RA subjects (HR: 1.57; 95% CI: 1.09–2.24).Conclusion. In patients with RA, hyperuricemia was a significant predictor of peripheral arterial events and mortality but not of CVD.
Abstract 2198: Possible circadian modulation of dihydropyrimidine dehydrogenase by mir-27a and mir-27b.
Butterfield, Gabriel L. , Diasio, Robert B. , Offer, Steven M.

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 8_Supplement | Pages: 2198-2198

10.1158/1538-7445.am2013-2198 Get It

Abstract 5-fluorouracil (5-FU) is a commonly administered chemotherapy drug used for the treatment of various aggressive cancers. Dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene) is the rate limiting enzyme of the 5-flourouracil (5-FU) catabolic pathway, and as such limits the amount of drug available for conversion into active metabolites. Reduced expression of DPD has been linked to severe adverse toxicity to 5-FU, including mucositis, diarrhea, hematological toxicities, and, in extreme cases, death. DPD has been previously shown to follow circadian patterns of expression in rodent models and in humans. Many microRNAs also exhibit circadian variations in expression and have been suggested to control oscillations in target protein expression. Using in silico prediction, we identified two putative binding domains for the microRNAs mir-27a and mir-27b within the DPYD gene. One of these sites is located in the 3’ untranslated region (UTR) and the other is located within the coding region just upstream from the stop codon. Using a reporter system, we show that mir-27a and mir-27b are able to bind to both predicted binding sites. Furthermore, over-expression of either microRNA reduced endogenous DPD protein levels in the HT-29 colon cancer cell line. To investigate mir-27a/b as a potential circadian regulator of DPD expression, expression was measured in livers collected at 4-hour intervals from chrono-synchronized mice. As expected, the circadian pattern of DPD enzyme activity closely matched that of DPD expression. The expression patterns for mir-27a and mir-27b were inverse of those for DPD expression and activity. These data suggest that mir-27a and mir-27b may direct circadian variations in DPD enzyme activity. Citation Format: Gabriel L. Butterfield, Steven M. Offer, Robert B. Diasio. Possible circadian modulation of dihydropyrimidine dehydrogenase by mir-27a and mir-27b. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2198. doi:10.1158/1538-7445.AM2013-2198
The Clinical Translation Gap in Child Health Exercise Research: A Call for Disruptive Innovation
Ashish, Naveen, Bamman, Marcas M. , Cerny, Frank, Cooper, Dan M. , d’Hemecourt, Pierre A., Eisenmann, Joey C., Ericson, Dawn, Fahey, John T., Gabriel, Davera , Leu, Szu‐Yun, McMurray, Robert G. , Nixon, Patricia A. , Olin, J. Tod , Pianosi, Paolo T. , Purucker, Mary, Radom‐Aizik, Shlomit , Taylor, Amy, Falk, Bareket , Kahn, Michael G. , Kemper, Han C. G. , Liem, Robert I. , Pianosi, P T

Clinical and Translational Science | August 11, 2014 | Volume: 8 | Issue: 1 | Pages: 67-76

10.1111/cts.12194 | PMID 25109386 Get It

Postoperative Infection Rates in Patients with a Negative Baseline Urine Culture Undergoing Ureteroscopic Stone Removal: A Matched Case–Control Analysis on Antibiotic Prophylaxis from the CROES URS Global Study
Мартов, А Г, Gravas, Stavros , Etemadian, Masoud , Ünsal, Ali , Barusso, Gabriel, D’Addessi, Alessandro, Krambeck, Amy E. , Rosette, Jean de la

Journal of Endourology | July 29, 2014 | Volume: 29 | Issue: 2 | Pages: 171-180

10.1089/end.2014.0470 | PMID 25072350 Get It

Purpose: To examine the effects of antibiotic prophylaxis on postoperative infection rate in patients with negative urine cultures undergoing ureteroscopy (URS). Patients and Methods: Using the Clinical Research Office of the Endourological Society (CROES) URS Global Study database, patients with a negative baseline urine culture undergoing URS for ureteral stones ( n =1141) or kidney stones ( n =184) not receiving antibiotic prophylaxis were matched with those who were predefined by risk factors, including gender, American Society of Anesthesiologists (ASA) score, and ureteral stent placement. Patient characteristics, operative data, and postoperative outcomes, including the development of urinary tract infection (UTI) and fever, in the two groups were compared. Results: Antibiotic prophylaxis use differed widely across participating countries (13%–100%). Differences were found between patients who did or did not receive antibiotic prophylaxis regarding the frequency of anticoagulation medication, previous treatment with URS, stone burden, previous presence of kidney stones, duration of current URS, and complications post-URS. The prevalence of fever and UTI was low (≤2.2%) and similar in both groups. Factors predictive of postoperative UTI or fever were female gender, Crohn's and cardiovascular disease, a high stone burden, and an ASA score of II or higher. Conclusions: In patients with a negative baseline urine culture undergoing URS for ureteral or renal stones, rates of postoperative UTI and fever were not reduced by preoperative antibiotic prophylaxis. Female gender and a high ASA score were specific risk factors for postoperative infection in this patient group.
Using Sit-Stand Workstations to Decrease Sedentary Time in Office Workers: A Randomized Crossover Trial
Dutta, Nirjhar , Koepp, Gabriel A., Stovitz, Steven D. , Levine, James A. , Pereira, Mark A. , Pereira, Mark A

International Journal of Environmental Research and Public Health | June 26, 2014 | Volume: 11 | Issue: 7 | Pages: 6653-6665

10.3390/ijerph110706653 | PMID 24968210 Get It

Objective: This study was conducted to determine whether installation of sit-stand desks (SSDs) could lead to decreased sitting time during the workday among sedentary office workers. Methods: A randomized cross-over trial was conducted from January to April, 2012 at a business in Minneapolis. 28 (nine men, 26 full-time) sedentary office workers took part in a 4 week intervention period which included the use of SSDs to gradually replace 50% of sitting time with standing during the workday. Physical activity was the primary outcome. Mood, energy level, fatigue, appetite, dietary intake, and productivity were explored as secondary outcomes. Results: The intervention reduced sitting time at work by 21% (95% CI 18%–25%) and sedentary time by 4.8 min/work-hr (95% CI 4.1–5.4 min/work-hr). For a 40 h work-week, this translates into replacement of 8 h of sitting time with standing and sedentary time being reduced by 3.2 h. Activity level during non-work hours did not change. The intervention also increased overall sense of well-being, energy, decreased fatigue, had no impact on productivity, and reduced appetite and dietary intake. The workstations were popular with the participants. Conclusion: The SSD intervention was successful in increasing work-time activity level, without changing activity level during non-work hours.